未登录.png)
分享.png)
收藏分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 Exploring the clinical utility of Oncotype DX in ER+/HER2-, N0 and N1 breast cancer patients: Insights from a Romanian cohort探索Oncotype DX在ER+/HER2-, N0和N1乳腺癌患者中的临床应用价值：来自罗马尼亚队列的见解
Blidaru, A.; Zob, D.; Schenker, M.; Onisim, A.; Bodale, C.; Curca, R.; Negru, S.; Oprean, C.; Curescu, P.; Gafton, B.; Volovat, S.; Mihaila, R.; Filip, G.; Median, D.; Dediu, M.; Chetroiu, D.; Pantelimon, I.; Costovici, C.; Viisoreanu, C. G.; Titirez, V.; Mateescu, D.; Gal, C.; Vremes, G.; Stanculeanu, D. -L.; Tsoulos, N.; Kapetsis, G.; Giannoulakis, S.; Sires, A.; Chirnogea, A.; Maxim, A. -I.; Iorga, P.; Jinga, D. -C.; Nitipir, C. 分享 收藏 Interim Analysis Results from a European Disease Registry Study Aimed to Prospectively Observe Treatment Patterns and Outcomes in Patients with HER2+Unresectable Locally Advanced or Metastatic Breast CancerBalic, Marija; Costa, Luis; Ojaimi, Joseline; Oprean, Cristina Marinela; Coelho, Jose L. Passos; Pazos, Isabel; Puglisi, Fabio; Sanglier, Thibaut; Scandurra, Giuseppa; Schenker, Michael; Wahyudi, Laurentia A.; Zhbantov, Georgi; Timcheva, Constanta 分享 收藏 分享 收藏 Unilateral Orbital Metastasis as the Unique Symptom in the Onset of Breast Cancer in a Postmenopausal Woman: Case Report and Review of the LiteratureOprean, Cristina Marinela; Badau, Larisa Maria; Segarceanu, Nusa Alina; Ciocoiu, Andrei Dorin; Rivis, Ioana Alexandra; Vornicu, Vlad Norin; Hoinoiu, Teodora; Grujic, Daciana; Bredicean, Cristina; Dema, Alis 分享 收藏 Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)Duligotuzumab (MEHD7945A) 与西妥昔单抗在头颈部鳞状细胞癌中的随机II期研究 (MEHGAN研究)Fayette, Jerome; Wirth, Lori; Oprean, Cristina; Udrea, Anghel; Jimeno, Antonio; Rischin, Danny; Nutting, Christopher; Harari, Paul M.; Csoszi, Tibor; Cernea, Dana; O'Brien, Paul; Hanley, William D.; Kapp, Amy V.; Anderson, Maria; Penuel, Elicia; McCall, Bruce; Pirzkall, Andrea; Vermorken, Jan B. 分享 收藏 A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapyAapro, M.; Rugo, H.; Rossi, G.; Rizzi, G.; Borroni, M. E.; Bondarenko, I.; Sarosiek, T.; Oprean, C.; Cardona-Huerta, S.; Lorusso, V.; Karthaus, M.; Schwartzberg, L.; Grunberg, S. 分享 收藏 CELER: an international randomized phase III trial of the CESAR Group - or: Should chemotherapy be added to hormonal therapy in advanced breast cancer?Sirbu, D.; Oprean, C.; Negru, S.; Draganescu, M.; Valeanu, V.; Reichert, D.; Eder, S.; Moritz, B.; Edler, L.; Morant, R. 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png)
Current Oncology.png)
OAAI